The clinical performance of many cell‑based therapeutics and implantable biomaterials is limited by host immune recognition, leading to fibrotic encapsulation and loss of graft function. Systemic immunosuppression can reduce these responses but carries risks and long‑term complications. The authors evaluated a localized immunomodulatory strategy in which implanted, encapsulated cells continuously secrete immunoregulatory cytokines at the device site to modulate the peri‑implant microenvironment and prevent the foreign body response.
The approach uses retinal pigment epithelial cells encapsulated within alginate microcapsules. These encapsulated cells are engineered to continuously secrete cytokines, specifically interleukin‑10 (IL‑10) or interleukin‑12 (IL‑12), with the aim of locally altering immune activity around the implant. The alginate capsules serve both to contain the cytokine‑producing cells and to model biomaterial implants that are susceptible to pericapsular fibrosis.
In healthy rodent experiments, localized production of IL‑10 or IL‑12 from the encapsulated cytokine‑producing cells prevented the foreign body response to alginate capsules. The abstract reports prevention of typical fibrotic encapsulation in these models, indicating that sustained local cytokine delivery at the implant site can suppress the host fibrotic reaction that otherwise compromises implant function.
Mechanistic observations associated with the treatment included reduced expression of profibrotic genes and immune shifts consistent with regulation of macrophages and T cells. These findings support a cytokine‑mediated mechanism in which local IL‑10 or IL‑12 secretion alters cellular and molecular pathways that drive fibrosis and chronic inflammatory encapsulation. The abstract attributes prevention of the foreign body response to these immune regulatory effects, though detailed gene lists, cell phenotyping data, and signaling pathways are not provided in the abstract summary.
The authors tested the platform in a streptozotocin‑induced diabetic murine model (C57BL/6J) to assess a clinically relevant application: supporting coimplanted human islets. Coimplantation of human islets with IL‑10‑producing encapsulated cells attenuated pericapsular fibrosis, preserved islet viability, and restored normoglycemia. The abstract reports durability of glycemic control for up to 100 days and states that this duration was 4.76 times longer than islets implanted without cytokine‑producing cells. These results indicate that localized IL‑10 delivery can improve both structural and functional outcomes for encapsulated islet grafts in a diabetic rodent model.
To evaluate translational feasibility beyond rodents, IL‑10‑producing encapsulated cells were implanted in a healthy nonhuman primate. The abstract reports that IL‑10‑producing cells were effective in enabling the durability and function of encapsulated cells in this primate model. This observation suggests that the localized cytokine‑secreting cell strategy may be translatable to larger mammals and provides a step toward clinical applicability, although the abstract does not include detailed primate outcome measures, numbers, or duration beyond the statement of effectiveness.
Collectively, the findings suggest that localized cytokine delivery via encapsulated, cytokine‑producing cells can reduce fibrotic encapsulation and support durable graft function. The authors propose this strategy as a way to lessen reliance on systemic immunosuppression in contexts such as islet transplantation and other therapies that use implantable biomaterials. Localized immunomodulation may offer site‑restricted immune regulation that preserves implant function while avoiding systemic exposure to immunosuppressive agents.
The abstract presents core outcomes and proposed mechanisms but omits multiple experimental details in this summary. Specifics not reported here include exact numbers of animals used, quantitative cytokine secretion rates and kinetics, alginate capsule dimensions or compositions, dosing/ratio of cytokine‑producing cells to therapeutic cells (for coimplantation), histological scoring details, statistical analyses, and any safety or off‑target immune findings. Those experimental design elements and full data would need to be consulted in the full article for comprehensive assessment and reproducibility.
The study demonstrates that sustained, local delivery of IL‑10 or IL‑12 from alginate‑encapsulated cytokine‑secreting cells can prevent the foreign body response to alginate implants in healthy rodents, modulate profibrotic gene expression and immune cell phenotypes, extend functional survival of coimplanted human islets in a diabetic mouse model (up to 100 days, ~4.76× longer than islets alone), and show efficacy in a healthy nonhuman primate. These results support localized cytokine‑producing cell strategies as a promising path to reduce fibrotic encapsulation and improve durability of cellular implants, with potential to reduce the need for systemic immunosuppression in translational applications. The abstract does not provide the granular experimental parameters or full datasets, which are necessary for detailed evaluation and translation planning.